Okay, let's tackle this question about chloramphenicol resistance in Pseudomonas aeruginosa. First, I need to recall how chloramphenicol works. It's a protein synthesis inhibitor, right? It binds to the 50S ribosomal subunit, preventing peptide bond formation. So, resistance mechanisms would involve ways bacteria can avoid this.

Now, Pseudomonas aeruginosa is known for being multidrug-resistant. Common resistance mechanisms include efflux pumps, enzymatic inactivation, and target site modification. For chloramphenicol specifically, I remember that some bacteria produce enzymes that modify the antibiotic, making it inactive. For example, chloramphenicol acetyltransferases (CAT) acetylate the drug, which inactivates it.

Looking at the options, the correct answer should be the one that mentions enzymatic inactivation. Let me think about the other options. If the options included something like beta-lactamase production, that's incorrect because that's for beta-lactam antibiotics, not chloramphenicol. Efflux pumps might be a distractor here, but chloramphenicol resistance is more commonly due to enzymatic inactivation rather than efflux in P. aeruginosa. Also, mutations in the ribosomal RNA genes could be a mechanism for other antibiotics, but not the primary one here.

Wait, I should double-check. Are there any other resistance mechanisms for chloramphenicol in Pseudomonas? I think the main one is the acetyltransferase. So the correct answer would be enzymatic inactivation by acetylation. The clinical pearl here is that chloramphenicol resistance often involves acetylation, so students should remember that enzymatic modification is a key mechanism in Gram-negative bacteria like P. aeruginosa.

**Core Concept** Chloramphenicol resistance in bacteria, including *Pseudomonas aeruginosa*, often involves enzymatic modification of the drug. This mechanism inactivates the antibiotic by altering its structure, preventing it from binding to the bacterial ribosome.

**Why the Correct Answer is Right** *P. aeruginosa* develops chloramphenicol resistance primarily through the production of **chloramphenicol acetyltransferase (CAT)**. This enzyme catalyzes the transfer of an acetyl group to chloramphenicol, modifying its structure and blocking its binding to the 50S ribosomal subunit. This enzymatic inactivation is a classic example of a **Phase II metabolic resistance mechanism**.

**Why Each Wrong Option is Incorrect**
**Option A:** Beta-lactamase production is incorrect because this enzyme degrades beta-lactam antibiotics (e.g., penicillins, cephalosporins), not chloramphenicol.
**Option B:** Efflux pumps (e.g., MexAB-OprM in *P. aeruginosa*) are a common resistance mechanism but are typically associated with multidrug resistance to aminoglycosides or fluoroquinolones, not chloramphenicol.
**Option C:** Ribosomal RNA mutations alter the antibiotic’s target site but are rare in chloramphenicol resistance; this mechanism is more relevant for macrolides or aminoglycosides.

**Clinical Pearl / High-Yield Fact** Remember the **"ACET"** mnemonic for chloramphenicol resistance: **

✓ Correct Answer: C. Active efflux pumping out of the drug